Tafrodol

Tafrodol was the brand name of a combination drug composed of the opioid analgesic drug tapentadol and the muscle relaxant and sedative drug carisoprodol within the same pill.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Tafrodol was the brand name of a combination drug composed of the opioid analgesic drug tapentadol and the muscle relaxant and sedative drug carisoprodol within the same pill. It was manufactured by an Indian pharmaceutical company Aveo Pharmaceuticals and marketed primarily to consumers in West African countries such as Ghana, Nigeria and Cote d'Ivoire, from around 2018-2025 before being withdrawn from the market following safety concerns and issues with abuse.

In contrast to comparable combination drugs such as dexamyl and desbutal which were marketed for legitimate medical applications but later withdrawn, tafrodol was never approved as an analgesic and appears to have been marketed primarily for recreational use, but under the guise of a legitimate pharmaceutical product taking advantage of weak regulatory laws in the destination markets. This ultimately led to both the banning of the product in both India and various West African nations, as well as Aveo Pharmaceuticals losing its license to manufacture pharmaceuticals within India.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1367001747 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

5 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.